| Literature DB >> 22075225 |
Shao-Bin Yang1, Ai-Min Yang, Shu-Fang Su, Hui-Hui Wang, Ning-Bo Wang, Qiang Chen.
Abstract
Neuronostatin, a newly identified peptide encoded by the somatostatin (SST) gene, was proved to produce significant antinociceptive effect in mouse tail immersion test. However, the effect of neuronostatin on tonic pain was still not clear. The aim of this study was to investigate the effect of neuronostatin in the formalin test and its possible mechanism. We found that intracerebroventricular (i.c.v.) administration of neuronostatin (1, 3, 6, 12nmol/mouse) increased licking in a dose-related manner during the late phase, but did not affect the early phase of formalin test in mice. In addition, the hyperalgesic effect during the late phase was completely reversed by melanocortin 3/4 receptor antagonist SHU9119 (50pmol/mouse) or opioid receptor antagonist naloxone (5nmol/mouse), but not GABAA receptor antagonist bicuculline (1086pmol/mouse). These data suggested that the hyperalgesic response induced by neuronostatin was dependent upon the central melanocortin system and endogenous opioid system. In conclusion, these results indicated that neuronostatin may be a new neuropeptide with important role in the modulation of acute and tonic pain.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22075225 DOI: 10.1016/j.neulet.2011.10.064
Source DB: PubMed Journal: Neurosci Lett ISSN: 0304-3940 Impact factor: 3.046